This section of Viatris.com contains information that may not be suitable for use in all countries due to varied regulatory requirements, data protection requirements and practices or medical practices, and distinctions among product approval and commercial availability. The information contained in each news release or statement posted on this page is presented as of the date it was issued. The company undertakes no obligation to update the information for changes or subsequent events after the date it was originally issued.
- Mar 8, 2021Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation AerosolMilestone reinforces Viatris' commitment to complex products and innovative solutions to help increase patient access
- Feb 9, 2021Viatris to host its inaugural virtual Investor Day on March 1, 2021, as previously announced
- Dec 11, 2020Initiative to Ensure Company is Set Up to Meet its Stated Commitments in Order to Deliver Sustainable Value to Patients, Customers, Shareholders and other Stakeholders